Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Top Cited Papers
- 13 August 2018
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 36 (9) , 847-856
Abstract
Anti-PD-1 secreted by CAR-T cells remains localized to the tumor and improves therapeutic outcome in mice. The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding tumors can be enhanced by administering the cells in combination with immune checkpoint blockade inhibitors. Alternatively, the CAR construct has been engineered to coexpress factors that boost CAR-T cell function in the tumor microenvironment. We modified CAR-T cells to secrete PD-1-blocking single-chain variable fragments (scFv). These scFv-secreting CAR-T cells acted in both a paracrine and autocrine manner to improve the anti-tumor activity of CAR-T cells and bystander tumor-specific T cells in clinically relevant syngeneic and xenogeneic mouse models of PD-L1+ hematologic and solid tumors. The efficacy was similar to or better than that achieved by combination therapy with CAR-T cells and a checkpoint inhibitor. This approach may improve safety, as the secreted scFvs remained localized to the tumor, protecting CAR-T cells from PD-1 inhibition, which could potentially avoid toxicities associated with systemic checkpoint inhibition.Keywords
This publication has 45 references indexed in Scilit:
- Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune SystemCell Reports, 2018
- Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck CancerMolecular Therapy, 2017
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioningBlood, 2012
- Measurement of Fractional Synthetic Rates of Multiple Protein Analytes by Triple Quadrupole Mass SpectrometryClinical Chemistry, 2012
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTipsNature Protocols, 2007
- In-gel digestion for mass spectrometric characterization of proteins and proteomesNature Protocols, 2006